BORR vs NPKI

BORR's Piotroski F-Score of 4/9 indicates borderline financial health, while the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades below its Graham Number of $5.01 at $4.47, suggesting modest undervaluation, though forward P/E of -47.51 signals expected earnings deterioration. Strong operating and gross margins contrast with high debt/equity of 1.80 and inconsistent earnings growth, particularly the recent Q/Q EPS decline of -35.7%. Technical trend is weak at 10/100, but dividend strength and insider sentiment are below average, contributing to a cautious outlook.

NPKI exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally low Debt/Equity ratio of 0.08. However, the stock is currently trading at a significant premium, with a price of $16.35 well above both its Graham Number ($6.27) and Intrinsic Value ($12.39). While explosive revenue and earnings growth justify some premium, the combination of a bearish technical trend (10/100) and aggressive insider selling by the CFO and General Counsel suggests the stock may be overextended in the short term.